SCHEMBL2270296

SCHEMBL2270296

O=C(Nc1cc(Sc2ccccc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.62
PKM P14618 3/20 0.62
KMT2A Q03164 3/20 0.62
MAPT P10636 2/20 0.62
MEN1 O00255 2/20 0.62
GRIK1 P39086 2/20 0.62
KCNK2 O95069 5/20 0.53
KCNK10 P57789 5/20 0.53
MCL1 Q07820 1/20 0.52
BCL2A1 Q16548 1/20 0.52
KDM4D Q6B0I6 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
LTC4S Q16873 1/20 0.50
DHODH Q02127 1/20 0.50
ACLY P53396 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 1/20 0.48
GLA P06280 1/20 0.48
SERPINE1 P05121 1/20 0.47
PLK1 P53350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269880 0.86 KDM4E (0.60) TDP1PKMKMT2AMAPTMEN1
SCHEMBL14428397 0.83 MAPT (0.55) TDP1PKMKMT2AMAPTMEN1
SCHEMBL2271190 0.81 MCL1 (0.64) TDP1PKMKMT2AMAPTMEN1
SCHEMBL14090354 0.80 HDAC1 (0.65) TDP1PKMKMT2AMAPTMEN1
SCHEMBL2271365 0.78 PKM (0.70) TDP1PKMKMT2AMAPTMEN1
SCHEMBL637477 0.78 KMT2A (0.70) TDP1PKMKMT2AMAPTMEN1
SCHEMBL2272413 0.78 MEN1 (0.63) TDP1PKMKMT2AMAPTMEN1
SCHEMBL1056451 0.77 KMT2A (1.00) TDP1PKMKMT2AMAPTMEN1
SCHEMBL2275453 0.77 ACLY (0.76) TDP1PKMKMT2AMAPTMEN1
SCHEMBL14428119 0.77 PKM (0.68) TDP1PKMKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 TDP1 3823/4885PKM 2367/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.